STAT+: FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams
The U.S. Food and Drug Administration has scolded AbbVie for making false and misleading claims…
Category: AbbVie
STAT+: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors
WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 million last year to…
STAT+: Cerevel drug for Parkinson’s disease improved symptom control in trial
Cerevel Therapeutics, a neuroscience biotech that AbbVie is acquiring, reported that its drug for Parkinson’s…
STAT+: The biotech scoreboard for the second quarter: 32 stock-moving events to watch
Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second…
Humira’s legacy, CEO symbolism, and genomic surgery
What do CEOs owe the world? Did Humira break the system? And can you CRISPR…
STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira
AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it…
STAT+: More patients are getting their meds online. Big Pharma wants in on the action
Since the pandemic, patients have become increasingly comfortable with getting their medications online. Direct-to-consumer telehealth…
STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion
Abbvie announced Wednesday that it will purchase Cereval Therapeutics and its pipeline of experimental neurological…
AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
Are ADCs having a moment? Is CAR-T safe? And who’s to blame for failed trials?…